528 related articles for article (PubMed ID: 23686414)
1. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
O'Dell JR; Curtis JR; Mikuls TR; Cofield SS; Bridges SL; Ranganath VK; Moreland LW;
Arthritis Rheum; 2013 Aug; 65(8):1985-94. PubMed ID: 23686414
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
[TBL] [Abstract][Full Text] [Related]
3. Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.
Curtis JR; McVie T; Mikuls TR; Reynolds RJ; Navarro-Millán I; O'Dell J; Moreland LW; Bridges SL; Ranganath VK; Cofield SS
J Rheumatol; 2013 May; 40(5):572-8. PubMed ID: 23588939
[TBL] [Abstract][Full Text] [Related]
4. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.
Navarro-Millán I; Charles-Schoeman C; Yang S; Bathon JM; Bridges SL; Chen L; Cofield SS; Dell'Italia LJ; Moreland LW; O'Dell JR; Paulus HE; Curtis JR
Arthritis Rheum; 2013 Jun; 65(6):1430-8. PubMed ID: 23460074
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis.
Chen XX; Dai Q; Huang AB; Wu HX; Zhao DB; Li XF; Hu SX; Yang NP; Tao Y; Xu JH; Jiang LD; Bao CD
Clin Rheumatol; 2013 Jan; 32(1):99-108. PubMed ID: 23053688
[TBL] [Abstract][Full Text] [Related]
6. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.
Emery P; Breedveld F; van der Heijde D; Ferraccioli G; Dougados M; Robertson D; Pedersen R; Koenig AS; Freundlich B;
Arthritis Rheum; 2010 Mar; 62(3):674-82. PubMed ID: 20187135
[TBL] [Abstract][Full Text] [Related]
7. Therapies for active rheumatoid arthritis after methotrexate failure.
O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
[TBL] [Abstract][Full Text] [Related]
8. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.
Emery P; Breedveld FC; Hall S; Durez P; Chang DJ; Robertson D; Singh A; Pedersen RD; Koenig AS; Freundlich B
Lancet; 2008 Aug; 372(9636):375-82. PubMed ID: 18635256
[TBL] [Abstract][Full Text] [Related]
9. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
10. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.
Pope JE; Haraoui B; Thorne JC; Vieira A; Poulin-Costello M; Keystone EC
Ann Rheum Dis; 2014 Dec; 73(12):2144-51. PubMed ID: 23979914
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
[TBL] [Abstract][Full Text] [Related]
12. Etanercept for the treatment of rheumatoid arthritis.
Lethaby A; Lopez-Olivo MA; Maxwell L; Burls A; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2013 May; 2013(5):CD004525. PubMed ID: 23728649
[TBL] [Abstract][Full Text] [Related]
13. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
Koyama Y; Shiraishi H; Ohta T; Uchino A
Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
[TBL] [Abstract][Full Text] [Related]
14. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
Emery P; Genovese MC; van Vollenhoven R; Sharp JT; Patra K; Sasso EH
J Rheumatol; 2009 Jul; 36(7):1429-41. PubMed ID: 19369462
[TBL] [Abstract][Full Text] [Related]
15. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
17. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
18. Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.
Charles-Schoeman C; Yin Lee Y; Shahbazian A; Wang X; Elashoff D; Curtis JR; Navarro-Millán I; Yang S; Chen L; Cofield SS; Moreland LW; Paulus H; O'Dell J; Bathon J; Louis Bridges S; Reddy ST
Arthritis Rheumatol; 2017 Jan; 69(1):46-57. PubMed ID: 27483410
[TBL] [Abstract][Full Text] [Related]
19. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
Zhao J; Zhou W; Wu Y; Ji P; Yang L; Yan X; Zhang Z
BMC Med Inform Decis Mak; 2021 Mar; 21(1):83. PubMed ID: 33663487
[TBL] [Abstract][Full Text] [Related]
20. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
